Interpreting the downstream effects of BRAF mutations, especially by stage and systemic therapy use, is challenged by the accuracy of stage recording in national data and the changing landscape of systemic therapy, with the approval of adjuvant BRAF/MEK inhibitors for stage III melanoma in 2018, which may have confounded the dataset. This evidence concerns the gene BRAF and melanoma.